Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.

Rico CA, Berchiche YA, Horioka M, Peeler JC, Lorenzen E, Tian H, Kazmi MA, Fürstenberg A, Gaertner H, Hartley O, Sakmar TP, Huber T.

Biophys J. 2019 Aug 2. pii: S0006-3495(19)30648-4. doi: 10.1016/j.bpj.2019.07.043. [Epub ahead of print]

PMID:
31421836
2.

Brain-resident memory T cells generated early in life predispose to autoimmune disease in mice.

Steinbach K, Vincenti I, Egervari K, Kreutzfeldt M, van der Meer F, Page N, Klimek B, Rossitto-Borlat I, Di Liberto G, Muschaweckh A, Wagner I, Hammad K, Stadelmann C, Korn T, Hartley O, Pinschewer DD, Merkler D.

Sci Transl Med. 2019 Jun 26;11(498). pii: eaav5519. doi: 10.1126/scitranslmed.aav5519.

PMID:
31243152
3.

Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.

McBride JW, Malcolm RK, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Devlin B, Boyd P.

Int J Pharm. 2019 Jun 10;564:207-213. doi: 10.1016/j.ijpharm.2019.04.040. Epub 2019 Apr 15.

PMID:
30999049
4.

IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Yshii L, Pignolet B, Mauré E, Pierau M, Brunner-Weinzierl M, Hartley O, Bauer J, Liblau R.

JCI Insight. 2019 Apr 4;4(7). pii: 127001. doi: 10.1172/jci.insight.127001. eCollection 2019 Apr 4.

5.

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES.

McBride JW, Boyd P, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Malcolm RK.

J Control Release. 2019 Mar 28;298:1-11. doi: 10.1016/j.jconrel.2019.02.003. Epub 2019 Feb 4.

6.

Rapid and low-cost multiplex synthesis of chemokine analogs.

Paolini-Bertrand M, Cerini F, Martins E, Scurci I, Hartley O.

J Biol Chem. 2018 Dec 7;293(49):19092-19100. doi: 10.1074/jbc.RA118.004370. Epub 2018 Oct 10.

PMID:
30305389
7.

CCR5: Established paradigms and new frontiers for a 'celebrity' chemokine receptor.

Scurci I, Martins E, Hartley O.

Cytokine. 2018 Sep;109:81-93. doi: 10.1016/j.cyto.2018.02.018.

PMID:
29903576
8.

Preventing HIV transmission through blockade of CCR5: rationale, progress and perspectives.

Hartley O, Martins E, Scurci I.

Swiss Med Wkly. 2018 Jan 26;148:w14580. doi: 10.4414/smw.2018.14580. eCollection 2018.

9.

Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population.

Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Hartley O, Montecucco F, Mach F, Kutalik Z, Waeber G, Vollenweider P, Vuilleumier N.

Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2342-2349. doi: 10.1161/ATVBAHA.117.309602. Epub 2017 Oct 26.

10.

Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00965-17. doi: 10.1128/AAC.00965-17. Print 2017 Oct.

11.

Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1.

Yuzugulen J, Douthwaite JA, Wood EG, Villar IC, Patel NSA, Jegard J, Gaertner H, Rossitto-Borlat I, Rose K, Hartley O, Cutillas PR, Ahluwalia A, Corder R.

Sci Rep. 2017 Jul 10;7(1):4956. doi: 10.1038/s41598-017-05365-2.

12.

Recombinant Antibodies for Academia: A Practical Approach.

Cosson P, Hartley O.

Chimia (Aarau). 2016 Dec 21;70(12):893-897. doi: 10.2533/chimia.2016.893.

PMID:
28661364
13.

Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.

Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Hartley O, Montecucco F, Mach F, Kutalik Z, Waeber G, Vollenweider P, Vuilleumier N.

Front Immunol. 2017 Apr 18;8:437. doi: 10.3389/fimmu.2017.00437. eCollection 2017.

14.

Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.

Fagète S, Botas-Perez L, Rossito-Borlat I, Adea K, Gueneau F, Ravn U, Rousseau F, Kosco-Vilbois M, Fischer N, Hartley O.

Protein Eng Des Sel. 2017 Sep 1;30(9):575-582. doi: 10.1093/protein/gzx021.

PMID:
28444391
15.

Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage.

Cerini F, Offord R, McGowan I, Hartley O.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):768-777. doi: 10.1089/AID.2016.0199. Epub 2017 Mar 6.

PMID:
28177261
16.

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study.

Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F, Hartley O, Montecucco F, Mach F, Waeber G, Vollenweider P, Vuilleumier N.

Thromb Haemost. 2016 Sep 27;116(4):764-71. doi: 10.1160/TH16-03-0248. Epub 2016 Jul 7.

17.

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.

Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M.

Mol Ther. 2016 Sep;24(9):1675-85. doi: 10.1038/mt.2016.134. Epub 2016 Jul 5.

18.

Generating Chemokine Analogs with Enhanced Pharmacological Properties Using Phage Display.

Dorgham K, Cerini F, Gaertner H, Melotti A, Rossitto-Borlat I, Gorochov G, Hartley O.

Methods Enzymol. 2016;570:47-72. doi: 10.1016/bs.mie.2015.09.014. Epub 2015 Nov 14.

PMID:
26921941
19.

A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.

Cerini F, Gaertner H, Madden K, Tolstorukov I, Brown S, Laukens B, Callewaert N, Harner JC, Oommen AM, Harms JT, Sump AR, Sealock RC, Peterson DJ, Johnson SK, Abramson SB, Meagher M, Offord R, Hartley O.

Protein Expr Purif. 2016 Mar;119:1-10. doi: 10.1016/j.pep.2015.10.011. Epub 2015 Oct 24.

20.

The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?

Pagano S, Gaertner H, Cerini F, Mannic T, Satta N, Teixeira PC, Cutler P, Mach F, Vuilleumier N, Hartley O.

PLoS One. 2015 Jul 15;10(7):e0132780. doi: 10.1371/journal.pone.0132780. eCollection 2015.

21.

CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells.

Fox JM, Kasprowicz R, Hartley O, Signoret N.

J Leukoc Biol. 2015 Jul;98(1):59-71. doi: 10.1189/jlb.2A0414-193RR. Epub 2015 May 8.

22.

Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5.

Bönsch C, Munteanu M, Rossitto-Borlat I, Fürstenberg A, Hartley O.

PLoS One. 2015 Apr 29;10(4):e0125396. doi: 10.1371/journal.pone.0125396. eCollection 2015.

23.

δ-Conotoxins synthesized using an acid-cleavable solubility tag approach reveal key structural determinants for NaV subtype selectivity.

Peigneur S, Paolini-Bertrand M, Gaertner H, Biass D, Violette A, Stöcklin R, Favreau P, Tytgat J, Hartley O.

J Biol Chem. 2014 Dec 19;289(51):35341-50. doi: 10.1074/jbc.M114.610436. Epub 2014 Oct 28.

24.

Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.

Teixeira PC, Ducret A, Ferber P, Gaertner H, Hartley O, Pagano S, Butterfield M, Langen H, Vuilleumier N, Cutler P.

J Biol Chem. 2014 Oct 10;289(41):28249-59. doi: 10.1074/jbc.M114.589002. Epub 2014 Aug 28.

25.

Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.

Vuilleumier N, Montecucco F, Hartley O.

World J Cardiol. 2014 May 26;6(5):314-26. doi: 10.4330/wjc.v6.i5.314. Review.

26.

Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Jin J, Colin P, Staropoli I, Lima-Fernandes E, Ferret C, Demir A, Rogée S, Hartley O, Randriamampita C, Scott MG, Marullo S, Sauvonnet N, Arenzana-Seisdedos F, Lagane B, Brelot A.

J Biol Chem. 2014 Jul 4;289(27):19042-52. doi: 10.1074/jbc.M114.559831. Epub 2014 May 22.

27.

Coordinate-based co-localization-mediated analysis of arrestin clustering upon stimulation of the C-C chemokine receptor 5 with RANTES/CCL5 analogues.

Tarancón Díez L, Bönsch C, Malkusch S, Truan Z, Munteanu M, Heilemann M, Hartley O, Endesfelder U, Fürstenberg A.

Histochem Cell Biol. 2014 Jul;142(1):69-77. doi: 10.1007/s00418-014-1206-1. Epub 2014 Mar 13.

PMID:
24623038
28.

Characterization of structure, dynamics, and detergent interactions of the anti-HIV chemokine variant 5P12-RANTES.

Wiktor M, Hartley O, Grzesiek S.

Biophys J. 2013 Dec 3;105(11):2586-97. doi: 10.1016/j.bpj.2013.10.025.

29.

Quantitative morphological analysis of arrestin2 clustering upon G protein-coupled receptor stimulation by super-resolution microscopy.

Truan Z, Tarancón Díez L, Bönsch C, Malkusch S, Endesfelder U, Munteanu M, Hartley O, Heilemann M, Fürstenberg A.

J Struct Biol. 2013 Nov;184(2):329-34. doi: 10.1016/j.jsb.2013.09.019. Epub 2013 Sep 30.

PMID:
24091038
30.

Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.

Wang NX, Sieg SF, Lederman MM, Offord RE, Hartley O, von Recum HA.

Mol Pharm. 2013 Oct 7;10(10):3564-73. doi: 10.1021/mp3007242. Epub 2013 Aug 26.

31.

HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.

Colin P, Bénureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J, Hartley O, Brelot A, Arenzana-Seisdedos F, Lagane B.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9475-80. doi: 10.1073/pnas.1222205110. Epub 2013 May 21.

32.

Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest.

Kavanagh JN, Currell FJ, Timson DJ, Savage KI, Richard DJ, McMahon SJ, Hartley O, Cirrone GA, Romano F, Prise KM, Bassler N, Holzscheiter MH, Schettino G.

Sci Rep. 2013;3:1770. doi: 10.1038/srep01770.

33.

Identification, structural and pharmacological characterization of τ-CnVA, a conopeptide that selectively interacts with somatostatin sst3 receptor.

Petrel C, Hocking HG, Reynaud M, Upert G, Favreau P, Biass D, Paolini-Bertrand M, Peigneur S, Tytgat J, Gilles N, Hartley O, Boelens R, Stocklin R, Servent D.

Biochem Pharmacol. 2013 Jun 1;85(11):1663-71. doi: 10.1016/j.bcp.2013.03.019. Epub 2013 Apr 5.

PMID:
23567999
34.

CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.

Choi WT, Nedellec R, Coetzer M, Colin P, Lagane B, Offord RE, Hartley O, Mosier DE.

J Virol. 2012 Sep;86(18):10218-20. doi: 10.1128/JVI.00353-12. Epub 2012 Jul 11.

35.

Mechanism and molecular basis for the sodium channel subtype specificity of µ-conopeptide CnIIIC.

Markgraf R, Leipold E, Schirmeyer J, Paolini-Bertrand M, Hartley O, Heinemann SH.

Br J Pharmacol. 2012 Oct;167(3):576-86. doi: 10.1111/j.1476-5381.2012.02004.x.

36.

Alteration of synaptic network dynamics by the intellectual disability protein PAK3.

Dubos A, Combeau G, Bernardinelli Y, Barnier JV, Hartley O, Gaertner H, Boda B, Muller D.

J Neurosci. 2012 Jan 11;32(2):519-27. doi: 10.1523/JNEUROSCI.3252-11.2012.

37.

A novel µ-conopeptide, CnIIIC, exerts potent and preferential inhibition of NaV1.2/1.4 channels and blocks neuronal nicotinic acetylcholine receptors.

Favreau P, Benoit E, Hocking HG, Carlier L, D' hoedt D, Leipold E, Markgraf R, Schlumberger S, Córdova MA, Gaertner H, Paolini-Bertrand M, Hartley O, Tytgat J, Heinemann SH, Bertrand D, Boelens R, Stöcklin R, Molgó J.

Br J Pharmacol. 2012 Jul;166(5):1654-68. doi: 10.1111/j.1476-5381.2012.01837.x.

38.

Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots.

Shulman Z, Cohen SJ, Roediger B, Kalchenko V, Jain R, Grabovsky V, Klein E, Shinder V, Stoler-Barak L, Feigelson SW, Meshel T, Nurmi SM, Goldstein I, Hartley O, Gahmberg CG, Etzioni A, Weninger W, Ben-Baruch A, Alon R.

Nat Immunol. 2011 Dec 4;13(1):67-76. doi: 10.1038/ni.2173.

PMID:
22138716
39.

Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

PLoS One. 2011;6(7):e22020. doi: 10.1371/journal.pone.0022020. Epub 2011 Jul 8.

40.

Efficient orthogonal bioconjugation of dendrimers for synthesis of bioactive nanoparticles.

Gaertner HF, Cerini F, Kamath A, Rochat AF, Siegrist CA, Menin L, Hartley O.

Bioconjug Chem. 2011 Jun 15;22(6):1103-14. doi: 10.1021/bc1005653. Epub 2011 May 31.

PMID:
21574642
41.

Deciphering the code for retroviral integration target site selection.

Santoni FA, Hartley O, Luban J.

PLoS Comput Biol. 2010 Nov 24;6(11):e1001008. doi: 10.1371/journal.pcbi.1001008.

42.

Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, Riddick NE, Mercanti V, Hartley O, Lederman MM.

Blood. 2011 Jul 28;118(4):1015-9. doi: 10.1182/blood-2010-05-282509. Epub 2010 Nov 10.

43.

CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.

Escola JM, Kuenzi G, Gaertner H, Foti M, Hartley O.

J Biol Chem. 2010 Dec 31;285(53):41772-80. doi: 10.1074/jbc.M110.153460. Epub 2010 Nov 1.

44.

"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

J Virol. 2010 Jun;84(11):5842-5. doi: 10.1128/JVI.01907-09. Epub 2010 Mar 24.

45.

V-79 Chinese hamster cells irradiated with antiprotons, a study of peripheral damage due to medium and long range components of the annihilation radiation.

Kovacevic S, Bassler N, Hartley O, Knudsen H, Vranjes S, Garaj-Vrhovac V, Holzscheiter M.

Int J Radiat Biol. 2009 Dec;85(12):1148-56. doi: 10.3109/09553000903242081.

PMID:
19995240
46.

An engineered CX3CR1 antagonist endowed with anti-inflammatory activity.

Dorgham K, Ghadiri A, Hermand P, Rodero M, Poupel L, Iga M, Hartley O, Gorochov G, Combadière C, Deterre P.

J Leukoc Biol. 2009 Oct;86(4):903-11. doi: 10.1189/jlb.0308158. Epub 2009 Jul 1.

PMID:
19571253
47.

Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge.

Veazey RS, Ling B, Green LC, Ribka EP, Lifson JD, Piatak M Jr, Lederman MM, Mosier D, Offord R, Hartley O.

J Infect Dis. 2009 May 15;199(10):1525-7. doi: 10.1086/598685.

48.

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier D, Hartley O.

Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17706-11. doi: 10.1073/pnas.0805098105. Epub 2008 Nov 12.

49.

Chemokine analogues show suitable stability for development as microbicides.

Cerini F, Landay A, Gichinga C, Lederman MM, Flyckt R, Starks D, Offord RE, Le Gal F, Hartley O.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):472-6. doi: 10.1097/QAI.0b013e31818c953f.

PMID:
18989226
50.

Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination.

Dorgham K, Abadie V, Iga M, Hartley O, Gorochov G, Combadière B.

Vaccine. 2008 Jun 19;26(26):3252-60. doi: 10.1016/j.vaccine.2008.04.003. Epub 2008 Apr 24.

PMID:
18479788

Supplemental Content

Loading ...
Support Center